Clinical trials: Priming
Infant Immunity Response and Immunoglobulin Diversity
Infant Immunity Comparison of Breastfed and Bottlefed Infants
This study will follow 40 healthy, vaginally delivered infants that are primarily (>/- 75%) breast fed and 40 infants that are exclusively formula fed for at least the first 4 months of life from birth until 12 month age.
- Trial name
- NCT02568579
- Testing
- blood sample/ stool sample
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study…
- Trial name
- NCT04760730
- Testing
- AZD1222, rAd26-S
- Where
- United Arab Emirates
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Immunogenicity, Safety
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) with Pentabio® vaccine Primed with Recombinant Hepatitis B
- Trial name
- NCT04071379
- Testing
- Recombinant Hepatitis B + DTP-HB-Hib, Hep B + Pentabio (registered)
- Where
- 3 sites in Indonesia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Meningococcal Immunisation, Healthy Volunteers
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers
The purpose of the MEQ00073 study is to describe the immunogenicity and safety of a booster dose and persistence of a priming dose of MenACYW conjugate vaccine (MenQuadfi®) in adolescents who had been vaccinated approximately 10…
- Trial name
- NCT04936685
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
- Where
- 27 sites in Finland, Germany and 2 more
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
H9 Priming Study in Healthy Adults
The purpose of this research study is to determine whether prior exposure to A/H2N2 viruses is associated with better antibody (part of the immune system that fights infection) responses after vaccination with an A/H9N2 flu…
- Trial name
- NCT00617331
- Testing
- Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses.
- Trial name
- NCT00902824
- Testing
- ADVAX, TBC-M4
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Influenza, Influenza Immunisation
H3N2 M2SR in Pediatric Population
This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03553940
- Testing
- Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Quadrivalent MDCK Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Haemophilus Influenzae Type b, Neisseria Meningitidis
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year…
- Trial name
- NCT00326118
- Testing
- Haemophilus influenzae type b and meningococcal serogroup C (vaccine), Priorix™, Hiberix™
- Where
- 7 sites in Australia
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
This is an open-label, dose-escalation study to examine the safety, tolerability, and immunogenicity of adjuvanted Fusion Peptide Vaccine alone or in prime-boost regimens with adjuvanted Trimer 4571 and Trimer 6931 vaccines in…
- Trial name
- NCT05470400
- Testing
- FP conjugate vaccine (25 mcg), FP conjugate vaccine (200 mcg), Trimer 6931 (100 mcg)
- Where
- 6 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
- Trial name
- DNA-Ad (NCT00870987)
- Testing
- DNA vaccine prime, adenovirus type 5 vaccine boost
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
The purpose of this study is to evaluate the safety and immune response to two different HIV vaccine regimens in healthy, HIV-uninfected people in the United States and South Africa.
- Trial name
- NCT01927835
- Testing
- DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis A
Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®
The purpose of this study is to assess the long-term persistence of immunity to hepatitis A in adults who were vaccinated 21-25 years earlier with hepatitis A vaccine, Havrix®.
- Trial name
- NCT02124785
- Testing
- Blood sampling
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chikungunya, Chikungunya Fever
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60…
- Conditions
- Chikungunya, Chikungunya Fever, Chikungunya Virus Infection, Chikungunya Virus Infections
- Trial name
- NCT07394426
- Testing
- PepGNP-ChikV
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
HIV-1, HIV Infections
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
The goal of this study is to understand the safety, tolerability and immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd 5 HIV-1 gag/pol/nef) vaccine in healthy human volunteers compared…
- Trial name
- NCT00849680
- Testing
- Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Gait
Comparison of Two Exercise Interventions to Improve Gait in Older Persons
The purpose of this research study is to compare two different exercise treatments for walking problems in older adults. The investigators want to determine if participation in the exercise programs for 3 months will improve…
- Trial name
- PRIME (NCT01076413)
- Testing
- skill based exercise, aerobic conditioning
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Healthy Young Adult, Neurophysiology
Motor Cortex Plasticity Response to Theta-Burst Stimulation After Ketone Monoester Supplementation
Transcranial magnetic stimulation is a medical device that can alter motor cortical (M1) excitability through the scalp via various protocols.
- Trial name
- KME-TBS (NCT06799260)
- Testing
- Ketone Monoester (KME), iTBS, cTBS
- Where
- Malaysia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
HIV Infections
Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine
While antiretroviral drugs have shown great promise in reducing HIV replication and thus in reducing HIV/AIDS associated morbi-mortality and HIV transmission, the cost is substantial and side effects are a potentially limiting…
- Trial name
- NCT01407497
- Testing
- DNA HIVIS and MVA-CMDR, Saline solution
- Where
- Mozambique
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Saúde, Mozambique
Polio
Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine
The rationale for this study (IPV 002ABMG) is to evaluate and compare three doses of IPV, two doses of IPV plus one bOPV, and one dose of IPV plus two doses of bOPV in order to provide evidence for better immunization policy…
- Trial name
- IPV002ABMG (NCT01841671)
- Testing
- IPV, bOPV, mOPV type 2
- Where
- Chile
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- University of Chile
Corona Virus Infection
BBV152/BBV154 Heterologus Prime-Boost Study
All participants will be assessed for immunogenicity and safety endpoints and provide a blood sample before the administration of the first dose of IP.
- Trial name
- BBV152BBV154 (NCT05639998)
- Testing
- COVAXIN(BBV152), BBV154 Intranasal Vaccine
- Where
- 11 sites in India
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Malaria, Matrix M
Adjuvanting Viral Vectored Malaria Vaccines With Matrix M
ChAd63 METRAP and MVA METRAP are investigational vaccines for malaria which have been studied in clinical trials for 4 years, and 10 years, respectively.
- Trial name
- NCT01669512
- Testing
- Control Regimen, Low Dose Matrix M Regimen, Standard Dose Matrix M Regimen
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Oxford